Kent Industrial Co. Ltd. logo

Kent Industrial Co. Ltd. (6606)

Market Closed
12 Aug, 05:30
TWSE TWSE
NT$
27. 10
0
0%
NT$
- Market Cap
- P/E Ratio
- Div Yield
206,397 Volume
- Eps
NT$ 27.1
Previous Close
Add Transaction
Day Range
26.85 27.35
Year Range
23.2 28.15
Want to track 6606 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

6606 closed today higher at NT$27.1, an increase of 0% from yesterday's close, completing a monthly increase of 10.387% or NT$2.55. Over the past 12 months, 6606 stock gained 7.3267%.
6606 pays dividends to its shareholders, with the most recent payment made on Jul 15, 2026. The next estimated payment will be in In 11 months on Jul 15, 2027 for a total of NT$1.03.
The last earnings report, released on Jun 18, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

6606 Chart

Kent Industrial Co. Ltd. (6606) FAQ

What is the stock price today?

The current price is NT$27.10.

On which exchange is it traded?

Kent Industrial Co. Ltd. is listed on TWSE.

What is its stock symbol?

The ticker symbol is 6606.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Kent Industrial Co. Ltd. ever had a stock split?

No, there has never been a stock split.

Kent Industrial Co. Ltd. Profile

Health Care Providers & Services Industry
Healthcare Sector
Mr. Yeqing Zhu CEO
TWSE Exchange
TW0006606007 ISIN
DE Country
1,041 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

New Horizon Health Limited stands out as an investment holding entity deeply engaged in the innovation and development of cancer screening products focused on addressing colorectal, cervical, and various other cancers within the People's Republic of China. Since its establishment in 2015, with its headquarters located in Hangzhou, China, the company has committed itself to pushing the boundaries of medical diagnostics technology. Beyond its primary research and development operations, New Horizon Health Limited broadens its scope to include the provision of technical services, consultancy, and technology transfers. Additionally, it delivers medical services alongside engaging in the manufacturing and sales of medical and laboratory equipment, particularly fecal occult blood test kits. Notably, the company not only caters to domestic needs but also partakes in technological imports and exports, showcasing its global outlook in the medical diagnostics and equipment sector.

Products and Services

At the core of New Horizon Health Limited's offering lies a suite of innovative cancer screening products and medical services, designed to meet the varied needs of patients and healthcare providers alike:

  • ColoClear: Positioned as an early screening product for colon cancer, ColoClear exemplifies the company's pursuit of early detection solutions. This product allows for an efficient and non-invasive approach to identifying potential colon cancer markers, underscoring the company's commitment to advancing cancer diagnostics.
  • Pupu Tube: A self-administered fecal occult blood test product, the Pupu Tube is part of New Horizon Health Limited’s suite designed to simplify and encourage regular screening practices among individuals. Its user-friendly approach facilitates early detection of hidden blood in stool, which can be an early indicator of colorectal cancer.
  • UU Tube: Addressing the need for early detection of Helicobacter pylori, a bacteria linked to peptic ulcers and an increased risk of stomach cancer, the UU Tube is a self-test product allowing individuals to take proactive steps towards their gastrointestinal health.

In addition to these groundbreaking products, New Horizon Health Limited is also deeply immersed in the continuous research and development of medical diagnostic technologies. This involves not just the creation of new products, but also the provision of essential technical services, consultancy, and technology transfers that are crucial for the advancement of medical diagnostics. Alongside, the company offers medical services, further showcasing its comprehensive approach to cancer detection and diagnostics. Its engagement in the manufacturing and sales of laboratory equipment and fecal occult blood test kits, coupled with its active participation in technological imports and exports, paints a picture of a company that is as innovative as it is expansive in its offerings.

Contact Information

Address: T1 Building, Hangzhou, China, 310052
Phone: 86 57 1811 07210